Cloud DX’s Post-Surgical Monitoring Wearable Validated in Peer-Reviewed Study

Rhea-AI Summary

Cloud DX has announced validation of its Vitaliti™ continuous monitoring wearable through a peer-reviewed study, essential for the ~800,000 surgical patients in Canada annually. The device is compliant with ISO 81060-2:2018, paving the way for regulatory approval in 2022. This technology supports continuous monitoring, allowing timely interventions post-surgery to enhance patient outcomes. A partnership with Medtronic aims to broaden deployment, significantly impacting patient care. CEO Robert Kaul emphasized the innovation in post-surgical monitoring, addressing critical health changes during recovery.

Positive

• Validation of Vitaliti™ device opens pathway for regulatory approval starting in 2022.
• Continuous monitoring can significantly improve post-surgical patient outcomes.
• Partnership with Medtronic facilitates broad deployment of the technology, addressing a large patient population.

Negative

• None.

Cloud DX's Post-Surgical Monitoring Wearable Validated in Peer-reviewed Study For the ~800,000 ¹ Canadian surgery patients per year, continuous monitoring with Vitaliti™ could enable earlier intervention in cases of patient decline.

• Validation of Cloud DX's Vitaliti™ continuous monitoring device clears way for regulatory approval starting in 2022.
• Accurate continuous data collection supports earlier detection of changes in patient condition, enabling rapid interventions to improve patient outcomes.
• Clear opportunity to impact up to ~800,000 1 surgical patients per year in Canada, deliverable through recent partnership with medical technology leader Medtronic.

WATERLOO, ON / ACCESSWIRE / December 8, 2021 / Cloud DX (TSXV:CDX)(OTCQB:CDXFF), Leading Virtual Care Platform Cloud DX has announced publication of an independent peer-reviewed validation study of its unique Vitaliti™ product, a non-invasive wearable devices that provides continuous vital sign monitoring (CVSM) device. The study assessed regulatory compliance and post-surgery use in monitoring patients' vital signs in real-world conditions. The study found Vitaliti™ to be fully ISO 81060-2:2018 compliant for the continuous vital measurement, clearing the way for regulatory approval starting in 2022. The study also found that patients welcomed the comfortable, easy to use device. Instead of care teams taking vitals periodically after surgery, Cloud DX's Vitaliti™ was used for continuous monitoring, which could transform post-surgical care by enabling early detection if any deterioration occurs in patient health. On launch, Vitaliti™ will become a key component of Cloud DX's Connected Health™ ecosystem of remote monitoring technologies. Through Cloud DX's recent partnership with Medtronic Canada ULC (a subsidiary of Medtronic plc (MDT), a global leader in healthcare technology), wide deployment of Vitaliti™ is intended to initially improve post-operative care for surgical patients in Canada (up to 800,000 annually) and eventually in the United States (up to several million annually).

Cloud DX CEO and Founder, Robert Kaul, stated: "This third-party validation of our proprietary Vitaliti™ product can assure patients and doctors that Cloud DX is creating and bringing to market next-generation solutions for improving post-surgical outcomes or medical interventions in general. Today, patients' vital signs are only continuously monitored if they're in an ICU; in the rest of the hospital, monitoring is only periodic. That approach can miss a rapid change in health status. And when patients are discharged home without continuous vital sign monitoring after an operation, they're at risk for poor outcomes that may have been prevented if they'd had the benefit of early detection through cutting-edge biosensor technology like our Vitaliti™ product."

The independent study, titled " Continuous non-invasive remote automated blood pressure monitoring with novel wearable technology : A Preliminary Validation Study, " was conducted by researchers at the Population Health Research Institute (PHRI) and published in the Journal of Medical Internet Research (JMIR). Findings include that Vitaliti™ CVSM demonstrated continuous non-invasive blood pressure (cNIBP) measurement in compliance with international ISO 81060-2:2018 standards.

The authors of the paper include: Michael McGillion, Nazari Dvirnik, Stephen Yang, Emilie Belley-Côté, Andre Lamy, Richard Whitlock, Maura Marcucci, Flavia Borges, Emmanuelle Duceppe, Carley Ouellette, Marissa Bird, Sandra L Carroll, David Conen, Jean-Eric Tarride, Prathiba Harsha, Ted Scott, Amber Good, Krysten Gregus, Karla Sanchez, Pamela Benoit, Julian Owen, Valerie Harvey, Elizabeth Peter, Jeremy Petch, Jessica Vincent, Michelle Graham, and PJ Devereaux.

About Cloud DX
Accelerating virtual healthcare, Cloud DX is on a mission to make healthcare better for everyone. Our Connected Health™ remote patient monitoring platform is used by healthcare enterprises and care teams across North America to virtually manage chronic disease, enable aging in place, and deliver hospital-quality post-surgical care in the home. Our partners achieve better healthcare and patient outcomes, reduce the need for hospitalization or re-admission, and reduce healthcare delivery costs through more efficient use of resources. Cloud DX is the co-winner of the Qualcomm Tricorder XPRIZE, a 2021 Edison Award winner, a Fast Company "World Changing Idea" finalist, and one of "Canada's Ten Most Prominent Telehealth Providers."

Cloud DX Investor Site https://ir.clouddx.com/overview/default.aspx

Neither TSX Venture Exchange nor its Regulation Services Provider (as that term is defined in policies of the TSX Venture Exchange) accepts responsibility for the adequacy or accuracy of this release.

Social Links

Twitter https://twitter.com/CloudDX

Facebook https://www.facebook.com/clouddxinc/

LinkedIn https://www.linkedin.com/company/cloud-dx/

Instagram https://www.instagram.com/cloud.dx/

For media inquiries please contact:
Janine Scott
Marketing Lead
888-543-0944
janine.scott@CloudDX.com

For investor inquiries please contact:
Jay Bedard
Cloud DX Investor Relations
647-881-8418
jay.bedard@CloudDX.com

SOURCE: Cloud DX Inc.

View source version on accesswire.com:
https://www.accesswire.com/676656/Cloud-DXs-Post-Surgical-Monitoring-Wearable-Validated-in-Peer-Reviewed-Study

FAQ

What is Cloud DX's Vitaliti™ device?

Vitaliti™ is a non-invasive wearable device that provides continuous vital sign monitoring for post-surgical care.

What does the recent study on Vitaliti™ demonstrate?

The study validates that Vitaliti™ complies with ISO 81060-2:2018 standards for continuous vital measurements.

How many surgical patients could benefit from Vitaliti™ in Canada?

Approximately 800,000 surgical patients per year in Canada could benefit from the Vitaliti™ device.

When can the Vitaliti™ device receive regulatory approval?

Regulatory approval for the Vitaliti™ device is anticipated to begin in 2022.

What is the significance of Cloud DX's partnership with Medtronic?

The partnership with Medtronic aims to enhance the deployment of Vitaliti™, improving post-operative care for surgical patients.